Dengue and other hemorrhagic viral fevers;Dengue y otras fiebres hemorrágicas virales

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 10, 2005, Pages 615-626

  Domingo Carrasco, Cristina ^a   Gascón Bustrenga, Joaquín ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Arenavirus; Bunyavirus; Filovirus; Flavivirus; Viral hemorrhagic fevers

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

ARENAVIRUS; BLEEDING DISORDER; BUNYAVIRUS; DENGUE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; EBOLA VIRUS; FILOVIRIDAE; FLAVIVIRUS; HEMORRHAGIC FEVER; HUMAN; LABORATORY DIAGNOSIS; MARBURG VIRUS; REVIEW; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 29444455497     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(05)75042-4     Document Type: Article

References (53)

1. Ter Meulen J. Response to haemorrhagic fevers in Europe. Lancet 2000;356 Suppl:64.
2. Lindeboch BD, Rice CM. Flarividiae: The viruses and their replication. En: Knipe DM, Howley HP, editors. Philadelphia: Lippincott Williams & Wilkins; 2001.
3. Solomon T. Viral Haemorrhagic Fevers. En: Cook G, Zumla, A., editors. Manson's Tropical Diseases. 21st ed. London: Elsevier Science; 2003: p. 773-93.
4. International Committee on Taxonomy of Viruses I. The Universal Virus Database of the ICTV. Volume 2005. 2002.
5. Cummins D. Arenaviral haemorrhagic fevers. Blood Rev. 1991;5:129-37.
6. Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis. 1995;1:55-7.
7. World Health Organization W. Dengue Haemorrhagic Fever: Diagnosis, Treatment, and Control. Genève: WHO; 1997.
8. Gascón J, Giner V, Vidal J, Jou JM, Mas E, Corachan M. Dengue: a re-emerging disease. A clinical and epidemiological study in 57 Spanish travelers. Med Clin (Barc). 1998;111:583-6.
9. World Health Organization W. Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec. 2003;78:349-59.
10. LeDuc JW. Epidemiology of hemorrhagic fever viruses. Rev Infect Dis. 1989;11 Suppl 4:730-5.
11. Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis. 2004;10:40-7.
12. Colebunders R, Mariage JL, Coche JC, Pirenne B, Kempinaire S, Hantson P, et al. A Belgian traveler who acquired yellow fever in the Gambia. Clin Infect Dis. 2002;35:e113-6.
13. Hirabayashi Y, Oka S, Goto H, Shimada K, Kurata T, Fisher-Hoch SP, et al. The first imported case of Lassa fever in Japan. Nippon Rinsho. 1989;47:71-5.
14. Haas WH, Breuer T, Pfaff G, Schmitz H, Kohler P, Asper M, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis. 2003;36:1254-8.
15. Lassa fever imported to England. Commun Dis Rep CDR Wkly. 2000;10:99.
16. Lassa fever, imported case, Netherlands. Wkly Epidemiol Rec. 2000;75:265.
17. Mahdy MS, Chiang W, McLaughlin B, Derksen K, Truxton BH, Neg K. Lassa fever: the first confirmed case imported into Canada. Can Dis Wkly Rep. 1989;15:193-8.
18. McCormick JB, Fisher-Hoch SP. Lassa fever. Curr Top Microbiol Immunol. 2002;262:75-109.
19. Maiztegui JI. Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ. 1975;52:567-75.
20. Charrel RN, De Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res. 2003;57:89-100.
21. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res. 2004;64:145-60.
22. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis. 2003;37:1084-92.
23. Halstead SB. The pathogenesis of dengue: the Alexander D Langmuir Lecture. Am J Trop Med Hyg. 1981;18:573-9.
24. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol. 2003;27:1-13.
25. Mairuhu AT, MacGillavry MR, Setiati TE, Soemantri A, Ten Gate H, Brandjes DP, et al. Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis. 2003;3:33-41.
26. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, De C, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol. 1999;73:4738-47.
27. Monath TP, Barrett AD. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003;60:343-95.
28. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004;4:487-98.
29. Shope RE. Bunyaviral fevers: Rift Valley fever and Crimean Congo Hemorrhagic fever. En: Guerrant RL, Weller PF, editors. Tropical Infectious Diseases: principles, pathogens and practice. Volume 2. Phyladelphia: Churchill Livingstone; 1999. p. 1213-6.
30. Nabeth P, Kane Y, Abdalahi MO, Diallo M, Ndiaye K, Ba K, et al. Rift Valley Fever Outbreak, Mauritania, 1998: Seroepidemiologic, Virologic, Entomologic and Zoologic Investigations. Emerging Infect Dis. 2001;7:1052-54.
31. Nakounne E, Selekon B, Morvan, J. Microbiological surveillance: viral hemorrhagic fever in Central African Republic: current serological data in man. Bull Soc Pathol Exot. 2000;93:3430-7.
32. Bossi P, Tegnell A, Baka A, Van Loock F, Hendricks J, Werner A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Eurosurveillance. 2004;9.
33. Cummins D, McCormick JB, Bennett D, Samba JA, Farrar B, Machin SJ, et al. Acute sensorineural deafness in Lassa fever. JAMA. 1990;264:2093-6.
34. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med. 1986;314:20-6.
35. Enria D, Briggiler AM, Fernández NJ, Levis SC, Maiztegui JI. Importance of dose neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984;2:255-6.
36. Guimard Y, Bwaka MA, Colebunders R, Calain P, Massamba M, De Roo A, et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 Suppl 1:8268-73.
37. White H. Lassa fever: a study of 23 hospitals cases. Trans R Soc Trop Med Hyg. 1973;22:773-9.
38. Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, et al. Neurological manifestations of dengue infection. Lancet. 2000;355:1053-9.
39. Gunther S, Weisner B, Roth A, Grewing T, Asper M, Drosten C, et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J Infect Dis. 2001;184:345-9.
40. Schmitz H, Kohler B, Laue T, Drosten C, Veldkamp PJ, Gunther S, et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 2002;4:43-50.
41. Centers for Disease Control (CDC) and National Institutes of Health. Recomended Biosafety Levels for Infectious Agents and Infected Animals (sections VI-VII). En: Richmond JY. aMR, editor. Biosafety in Microbiological and Biomedical Laboratoires. Washington: U.S. Department of Health and Human Services; 1999.
42. Real Decreto 664/1997, sobre la protección de los trabajadores contra los riesgos relacionados con la exposición a agentes biológicos. RD664/1997, 1997:BOE n.° 124.
43. Drosten C, Kummerer BM, Schmitz H, Gunther S. Molecular diagnostics of viral hemorrhagic fevers. Antiviral Res. 2003;57:61-87.
44. Guzman MG, Kouri G. Dengue diagnosis, advances and challenges. Int J Infect Dis. 2004;8:69-80.
45. Teles FR, Prazeres DM, Lima-Filho JL. Trends in dengue diagnosis. Rev Med Virol. 2005.
46. Sanchez A, Ksiazek TG, Rollin PE, Miranda ME, Trappier SG, Khan AS, et al. Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J Infect Dis. 1999;179 Suppl 1:164-9.
47. Sail AA, Thonnon J, Sene OK, Fall A, Ndiaye M, Baudez B, et al. Single-tube and nested reverse transcriptase-polymerase chain reaction for detection of Rift Valley fever virus in human and animal sera. J Virol Methods. 2001;91:85-92.
48. Sanchez-Seco MP, Rosario D, Domingo C, Hernández L, Valdes K, Guzman MG, et al. Generic RT-nested-PCR for detection of flaviviruses using degenerated primers and internal control followed by sequencing for specific identification. J Virol Methods. 2005;126:101-9.
49. Lozano ME, Posik DM, Albarino CG, Schujman G, Ghiringhelli PD, Calderon G, et al. Characterization of arenaviruses using a family-specific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses. Virus Res. 1997;49:79-89.
50. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-30.
51. Kuno G. Serodiagnosis of flaviviral infections and vaccinations in humans. Adv Virus Res. 2003;61:3-65.
52. Bausch DG, Rollin PE, Demby AH, Coulibaly M, Kanu J, Conteh AS, et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol. 2000;38:2670-7.
53. Maiztegui JI, McKee KT Jr, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis. 1998;177:277-83.